Drugs

Petition urges FDA to Ban Gadolinium MRI Contrast Agents

A physician has asked FDA to impose an immediate moratorium on the use of gadolinium-based contrast agents in MRI scans, arguing that a growing body of scientific literature demonstrates the agents can cause widespread and potentially permanent health effects. In a just-posted citizen petition, Regina Sutton called on the agency to take emergency action against gadolinium-containing MRI contrast agents, contending that their continued use presents "an immediate threat to public health and safety."

The petition arrives as regulators, radiologists and manufacturers continue to debate the clinical significance of gadolinium retention in the body, an issue that has been under FDA scrutiny for nearly a decade. The agency required class-wide labeling changes in 2017 warning that gadolinium can remain in the body for months or years after administration and directed manufacturers to conduct additional safety studies.

Sutton's filing cites more than 40 scientific publications and reviews that she says link gadolinium exposure to a broad range of adverse effects, including kidney injury, fibrosis, neurological impairment, cognitive dysfunction, mitochondrial toxicity, reproductive effects, inflammatory responses, and tissue deposition in the brain, bone and other organs.

Among the concerns raised in the petition are reports of nephrogenic systemic fibrosis, gadolinium deposition in brain tissue, neurotoxicity, hearing impairment, chronic pain syndromes, liver injury, reproductive toxicity, and immune-system dysfunction. The filing also cites studies suggesting gadolinium accumulation can occur even in patients without severe renal impairment.

The petition argues that newer publications strengthen concerns about gadolinium retention and its biological effects. Sutton points to recent studies examining macrophage dysfunction, astrocyte signaling, neuronal effects, mitochondrial injury, behavioral changes in animal models and cytokine-related inflammatory pathways.

Gadolinium-based contrast agents are widely used in MRI imaging to improve visualization of tumors, blood vessels and inflammatory lesions. While regulators worldwide have acknowledged that trace amounts of gadolinium can remain in the body after administration, FDA has historically maintained that available evidence has not established a causal link between gadolinium retention and adverse health effects in patients with normal kidney function.

Sutton's petition goes substantially further, asserting that the existing evidence now supports a complete suspension of gadolinium-enhanced MRI procedures pending further review. She urged FDA to accelerate consideration of the request rather than wait for the agency's standard 180-day response timeline for citizen petitions.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome